CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...